EpiVax Expands Labs to Accelerate Immunogenicity Assessments
EpiVax, Inc., a company focused on immunogenicity risk assessment, has more than doubled its laboratory space in Providence, RI. The expansion addresses growing demand for new, human-relevant methods in evaluating immunogenicity risks.
EpiVax, Inc., a company specializing in immunogenicity risk assessment, has completed a significant expansion of its laboratory facilities in Providence, RI. The upgrade has more than doubled the company's laboratory footprint, increasing its capacity for advanced immunological testing.
The expansion comes in response to a growing demand for integrated, human-relevant "new approach methodologies" (NAMs) for evaluating immunogenicity risks. Limitations of traditional animal models in providing human-relevant readouts have driven the need for more reliable methods.
In line with global regulatory guidance, NAMs are increasingly central to immunogenicity risk assessment for biologics and other therapeutics. EpiVax provides an integrated approach combining "in silico" tools with "in vitro" assays early in the development process.
The expanded labs support assessments using human blood and specialized antigen-presenting cells. EpiVax aims to provide data-driven solutions to partners, enabling informed decisions throughout the product development lifecycle, from discovery to commercialization.